ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

A study in healthy adult participants to assess the safety and tolerability of a drug called ELE-101 (psilocybin) and see how the body absorbs and removes the drug and how it affects the body.

Original title: ELE-101 Safety & Tolerability Study in Healthy Participants

Compound Psilocybin
Country United Kingdom
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Eleusis
Eleusis is a clinical-stage life sciences company that studies and develops psychedelic drugs for therapeutic use. Since 2013 the company has been researching psychedelics and is now developing ELE-Psilo (psilocybin) for depression that is in Phase I.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.